RT Journal Article
SR Electronic
T1 Anatomy of digital contact tracing: role of age, transmission setting, adoption and case detection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.22.20158352
DO 10.1101/2020.07.22.20158352
A1 Jesús A. Moreno López
A1 Beatriz Arregui García
A1 Piotr Bentkowski
A1 Livio Bioglio
A1 Francesco Pinotti
A1 Pierre-Yves Boëlle
A1 Alain Barrat
A1 Vittoria Colizza
A1 Chiara Poletto
YR 2020
UL http://medrxiv.org/content/early/2020/07/25/2020.07.22.20158352.abstract
AB The efficacy of digital contact tracing against COVID-19 epidemic is debated: smartphone penetration is limited in many countries, non-uniform across age groups, with low coverage among elderly, the most vulnerable to SARS-CoV-2. We developed an agent-based model to precise the impact of digital contact tracing and household isolation on COVID-19 transmission. The model, calibrated on French population, integrates demographic, contact-survey and epidemiological information to describe the risk factors for exposure and transmission of COVID-19. We explored realistic levels of case detection, app adoption, population immunity and transmissibility. Assuming a reproductive ratio R = 2.6 and 50% detection of clinical cases, a ∼20% app adoption reduces peak incidence of ∼36%. With R = 1.7, >30% app adoption lowers the epidemic to manageable levels. Higher coverage among adults, playing a central role in COVID-19 transmission, yields an indirect benefit for elderly. These results may inform the inclusion of digital contact tracing within a COVID-19 response plan.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partially supported by the ANR project DATAREDUX (ANR-19-CE46-0008-01) to AB, VC and PYB; EU H2020 grants MOOD (H2020-874850) to VC, CP, and PYB, and RECOVER (H2020-101003589) to VC; the Municipality of Paris (https://www.paris.fr/) through the programme Emergence(s) to JML, BAC, PB, FP and CP; the ANR and Fondation de France through the project NoCOV (00105995) to PYB, CP.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All relevant ethical guidelines have been followed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data needed to evaluate the conclusions in the paper are present in the paper or available from public sources cited on the paper.